Tutti gli studi
Attivo ma non reclutanteFASE3INTERVENTISTICO

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

This research study is investigating a new medication, Remibrutinib, for adults who have Generalized Myasthenia Gravis. The main aim is to understand if Remibrutinib is effective at helping with the symptoms of this condition, how safe it is, and whether people can tolerate it well. Participants will either receive Remibrutinib or a placebo (a dummy medicine that looks the same but has no active ingredient), in addition to their current, stable treatments. This will be done in a way that neither the patient nor their doctor knows who is getting which treatment at first. The study hopes to gather important information that could help improve future treatment options for Myasthenia Gravis.

A colpo d'occhio

Stato
Attivo ma non reclutante
Fase
FASE3
Sponsor
Novartis Farmaceutici
Obiettivo di iscrizione
180
Inizio
07 Feb 2025
Completamento stimato
26 Feb 2033

Di cosa tratta questo studio?

This study is about an illness called Generalized Myasthenia Gravis, which is a long-term condition that causes muscle weakness. It's looking into a new medicine called Remibrutinib. The main goal is to find out if this medicine can help improve symptoms, if it's safe to use, and if people find it easy to take, especially when they're already on their usual treatments.

To do this, some adult patients with Generalized Myasthenia Gravis will receive the new medicine, Remibrutinib, while others will get a placebo. A placebo looks just like the real medicine but contains no active ingredient. This is a common way to test new medicines, as it helps researchers see if any improvements are truly due to the new drug or something else. Neither the patients nor their doctors will know who is receiving which treatment during the first part of the study; this is called 'double-blind'.

Later, everyone will have the chance to take Remibrutinib. The study aims to involve around 180 people and split them into two groups. By carefully comparing the groups, experts hope to learn a lot about Remibrutinib and whether it could become a helpful new treatment option for people living with Generalized Myasthenia Gravis.

Punti chiave

  • This study is testing a new medicine (Remibrutinib) for Generalized Myasthenia Gravis.
  • It aims to see how well it works and if it's safe.
  • You would continue your existing Myasthenia Gravis treatments.
  • Participants will either receive Remibrutinib or a dummy drug (placebo) at first.
  • The study could last for several years, with regular check-ups.
  • Puoi smettere di partecipare in qualsiasi momento.

Chi può essere idoneo?

This study is looking for adults aged between 18 and 75 who have been diagnosed with Generalized Myasthenia Gravis. Your doctor will need to confirm you have a certain level of Myasthenia Gravis symptoms and are unlikely to need breathing support during the study.

You'll also need to have had specific antibody tests that confirm your Myasthenia Gravis, or show you don't have these antibodies. Your symptoms should include a certain level of daily activity difficulties, with at least half of these difficulties not related to your eyes. You must also be on a steady dose of your current Myasthenia Gravis treatments and be able to swallow the study medication safely.

There are also some reasons why you might not be able to join. For example, if you've recently had certain treatments like IV immunoglobulins, plasma exchange, or specific therapies such as rituximab, eculizumab, or efgartigimod within certain timeframes before the study. Also, if you've had surgery to remove your thymus gland in the last six months or plan to have one, you wouldn't be able to join. Women who could become pregnant must be using effective contraception throughout the study and for a week afterwards.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Are you an adult between 18 and 75 years old?
  2. Do you have a confirmed diagnosis of Generalized Myasthenia Gravis?
  3. Are your Myasthenia Gravis symptoms mostly affecting parts of your body other than your eyes?
  4. Are you currently on a stable dose of your usual Myasthenia Gravis treatments?
  5. Can you safely swallow medications, as checked by your doctor?
  6. Have you avoided certain other Myasthenia Gravis treatments (like IVIg/PLEX, rituximab, eculizumab, etc.) within specific recent timeframes?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you join this study, it will be split into two main parts. For the first six months, you will either receive Remibrutinib or a placebo, and neither you nor your doctors will know which one. This period involves regular visits to the clinic for assessments and to check how you're feeling and if the treatment is helping.

After these first six months, if you wish to continue, you could then enter an 'open-label' part of the study. This means everyone will receive Remibrutinib, and everyone will know they are receiving the active drug. This longer part could last for up to five years. Throughout the study, you'll have appointments to review your health, check for any side effects, and monitor your Myasthenia Gravis symptoms. The study medication will need to be swallowed, and your ability to do so will be assessed.

Rischi e benefici potenziali

Taking part in a study like this might offer a potential benefit if Remibrutinib helps improve your Myasthenia Gravis symptoms more than your current treatment or the placebo. However, there's also a chance you might experience side effects from the new medicine, or that it might not help your symptoms. The research team will carefully monitor you for any changes in your health. Remember, joining any clinical study is always voluntary, and you have the right to withdraw at any time without explaining your reasons, and this will not affect your future medical care.

Locations (120)

  • Neuromuscular Research Center
    Codice postale verificato
    Phoenix, Stati Uniti
  • Honor Health Research Institute
    Codice postale verificato
    Scottsdale, Stati Uniti
  • Fullerton Neuro and Headache Ctr
    Codice postale verificato
    Fullerton, United States
  • University Of Southern California
    Codice postale verificato
    Los Angeles, Stati Uniti
  • California Pacific Medical Center
    Codice postale verificato
    Sacramento, Stati Uniti
  • Medstar Washington Hospital Center
    Codice postale verificato
    Washington D.C., Stati Uniti
  • SFM Clinical Research LLC
    Codice postale verificato
    Boca Raton, United States
  • Homestead Assoc In Research Inc
    Codice postale verificato
    Homestead, United States
  • Neurology Associates PA
    Codice postale verificato
    Maitland, United States
  • AdventHealth
    Codice postale verificato
    Orlando, Stati Uniti
  • Neurological Services of Orlando PA
    Codice postale verificato
    Orlando, Stati Uniti
  • University of Chicago Medical Centr
    Codice postale verificato
    Chicago, Stati Uniti

Domande comuni

What is Generalized Myasthenia Gravis?

It's a long-term condition that causes muscle weakness throughout the body.

What is Remibrutinib?

It's a new medicine being tested to see if it can help people with Myasthenia Gravis.

What is a 'placebo'?

A placebo is a dummy medicine that looks like the real drug but contains no active ingredients. It's used for comparison.

Sapró se sto ricevendo il vero medicinale o il placebo?

For the first six months, neither you nor your doctor will know. After that, everyone will get the active medicine.

Quanto durerà lo studio?

The main part is six months, with an option to continue for up to five years.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.